The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy
Abstract
Breast cancer is the most malignant tumor in women, and there is no absolute cure for it. Although treatment modalities including surgery, chemotherapy, and radiotherapy are utilized for breast cancer, it is still a life‐threatening disease for humans. Nanomedicine has provided a new opportunity in breast cancer treatment, which is the focus of the current study. The nanocarriers deliver chemotherapeutic agents and natural products, both of which increase cytotoxicity against breast tumor cells and prevent the development of drug resistance. The efficacy of gene therapy is boosted by nanoparticles and the delivery of CRISPR/Cas9, Noncoding RNAs, and RNAi, promoting their potential for gene expression regulation. The drug and gene codelivery by nanoparticles can exert a synergistic impact on breast tumors and enhance cellular uptake via endocytosis. Nanostructures are able to induce photothermal and photodynamic therapy for breast tumor ablation via cell death induction. The nanoparticles can provide tumor microenvironment remodeling and repolarization of macrophages for antitumor immunity. The stimuli‐responsive nanocarriers, including pH‐, redox‐, and light‐sensitive, can mediate targeted suppression of breast tumors. Besides, nanoparticles can provide a diagnosis of breast cancer and detect biomarkers. Various kinds of nanoparticles have been employed for breast cancer therapy, including carbon‐, lipid‐, polymeric‐ and metal‐based nanostructures, which are different in terms of biocompatibility and delivery efficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Li, J., Huo, M., Wang, J., Zhou, J., Mohammad, J. M., Zhang, Y., Zhu, Q., Waddad, A. Y., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.022 · Cited by 468
Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells
Minafra, L., Porcino, N., Bravatà, V., Gaglio, D., Bonanomi, M., Amore, E., Cammarata, F. P., Russo, G., Militello, C., Savoca, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47553-2 · Cited by 108
Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles
Nosrati, H., Salehiabar, M., Charmi, J., Yaray, K., Ghaffarlou, M., Balcioglu, E., & Ertas, Y. N. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00965 · Cited by 73
Luo, K., Gao, Y., Yin, S., Yao, Y., Yu, H., Wang, G., & Li, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.029 · Cited by 70 · cited 1×
“This combination suppressed the proliferation and invasion of breast tumor cells.(153) Another study developed PEI/TPGS nanostructures for codelivery of PTX and Twist‐shRNA to impair the progression of breast cancer cells.”
BackgroundPreparation of alginate coated Pt nanoparticle for radiosensitization of breast cancer tumor
Rashidzadeh, H., Seidi, F., Ghaffarlou, M., Salehiabar, M., Charmi, J., Yaray, K., Nosrati, H., & Ertas, Y. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123273 · Cited by 43
Alendronate-modified polymeric micelles for the treatment of breast cancer bone metastasis
Liu, T., Romanova, S., Wang, S., Hyun, M. A., Zhang, C., Cohen, S. M., Singh, R. K., & Bronich, T. K. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01343 · Cited by 34 · cited 1×
“Polymeric micelles are of particular interest because of their easy‐to‐tailor structure.(179,180) Paclitaxel drug molecules were entrapped in an acid‐labile, bone‐modified, PEGylated micellar system.”
Background
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Green and sustainable synthesis of nanomaterials: Recent advancements and limitations
Gupta, D., Boora, A., Thakur, A., & Gupta, T. K. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116316 · Cited by 471
Feng, C., Wang, Y., Xu, J., Zheng, Y., Zhou, W., Wang, Y., & Luo, C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121582 · Cited by 317
Colak, B., & Ertas, Y. N. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17024 · Cited by 50
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35
Metadata
- Authors
- Ashrafizadeh, M., Zarrabi, A., Bigham, A., Taheriazam, A., Saghari, Y., Mirzaei, S., Hashemi, M., Hushmandi, K., Karimi‐Maleh, H., Nazarzadeh Zare, E., Sharifi, E., Ertas, Y. N., Rabiee, N., Sethi, G., & Shen, M.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2023-05-11
- Volume
- 43
- Issue
- 6
- Pages
- 2115-2176
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W4376131005
- Cited by
- 207
- References
- 8
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: (Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy. https://app.cochat.ai/papers/10.1002/med.21971
- The paper
- Ashrafizadeh, M., Zarrabi, A., Bigham, A., Taheriazam, A., Saghari, Y., Mirzaei, S., Hashemi, M., Hushmandi, K., Karimi‐Maleh, H., Nazarzadeh Zare, E., Sharifi, E., Ertas, Y. N., Rabiee, N., Sethi, G., & Shen, M. (2023). (Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy. Medicinal Research Reviews. https://doi.org/10.1002/med.21971
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.